BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Amgen In-Licensed Products by Year
Amgen In-Licensed Products — Total Net Product Revenue ($M) ($M)
BeOne Medicines Amgen In-Licensed Products: $486M in FY2025.
Latest, FY2025
486
Period ended Dec 31, 2025
Change on a year earlier
–
History
1 years
Since FY2025
Sources
1
Form 8-K (filed 2026-02-26)
Where the FY2025 figure comes from
“Amgen in-licensed products: Global sales totaled $112 million and $486 million for the fourth quarter and full year of 2025, representing growth of 11% and 33%”
Source: Form 8-K (filed 2026-02-26) ↗
Reported in Form 10-Q / 10-K MD&A & Segment Disaggregation Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Amgen In-Licensed Products — Total Net Product Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 486 | – | Form 8-K (filed 2026-02-26) ↗ |
Breakdown
What makes up amgen In-Licensed Products
Cite this data
StockData. (2026). BeOne Medicines Amgen In-Licensed Products ($M), annual FY2025–FY2025 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod-amgen-tot
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.